The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic…

HER2+ Metastatic Breast Cancer

~Estimated

~$150 – $3,000

Actual pay is set by the research site.

Duke UniversityNCT07136428

Observational

Evaluating a Patient Navigation Program to Improve Therapy Management for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, t…

HER2+ Metastatic Breast Cancer (MBC)

~Estimated

~$10 – $750

Actual pay is set by the research site.

Duke UniversityNCT06983691